World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 19 October 2017
Main ID:  NCT00814255
Date of registration: 22/12/2008
Prospective Registration: Yes
Primary sponsor: New York University School of Medicine
Public title: Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial FONTII
Scientific title: Novel Therapies for Resistant Focal Segmental Glomerulosclerosis
Date of first enrolment: December 2008
Target sample size: 32
Recruitment status: Completed
Study type:  Interventional
Study design:   
Phase:  Phase 2
Countries of recruitment
Canada United States
Name:     Howard Trachtman, MD
Affiliation:  NYU Langone Medical Center
Name:     Jennifer Gassman, PhD
Affiliation:  The Cleveland Clinic
Name:     Debbie Gipson, MD
Affiliation:  University of Michigan
Key inclusion & exclusion criteria

Inclusion Criteria:

- Primary FSGS confirmed by renal biopsy OR documentation of a genetic mutation in a
podocyte protein associated with the disease

- Failure to respond to prior therapy at least one of the following immunosuppressive
medications -- cyclosporine, tacrolimus, mycophenolate mofetil, sirolimus - or other
agents prescribed to lower proteinuria

- Age 1-65 years at onset of proteinuria

- Age 1-65 years at time of randomization

- Estimated GFR =40 mL/min/1.73 m2 using Schwartz (age <18 yr) or Cockroft-Gault (age
<18 yr) formula at screening and =30 mL/min/1.73 m2 at the end of the Run-In Period
and at the time of randomization

- Up/c > 1.0 g/g creatinine on first morning void

- Steroid resistance defined as failure to achieve sustained Up/c < 1.0 following a
standard course of prednisone/prednisolone/methylprednisolone prescribed for FSGS
therapy, OR contraindication/anticipated intolerance to steroid therapy defined as
severe obesity, documented decreased bone density, family history of diabetes, or a
psychiatric disorder.

- Willingness to follow the protocol, including medications, baseline and follow-up
visits, and procedures.

Exclusion Criteria:

- Lactation, pregnancy, or refusal of birth control in women of child bearing potential

- Participation in another therapeutic trial involving protocol mandated administration
of a immunosuppressive medication concurrently or 30 days prior to randomization

- Active/serious infection (including, but not limited to Hepatitis B or C, HIV)

- History of malignancy

- Abnormality in age appropriate cancer screening in accord with ACS 2003 guidelines
(appendix 17.6)

- Patients with uncontrolled blood pressure > 140/90 or > 95th percentile for age/height
at the end of the run in period

- Diabetes mellitus Type I or II

- Organ transplantation

- Congestive heart failure

- History of prior myocardial infarction

- SLE or multiple sclerosis

- Hepatic disease, defined as serum ALT/AST levels more than 2.5x the upper limit of

- Hematocrit <27%

- Immunosuppressive therapy with cyclosporine, tacrolimus, mycophenolate mofetil,
azathioprine, or rapamycin in the 30 days prior or Rituximab in the 90 days prior to

- Prior treatment with the study medications, rosiglitazone or adalimumab

- Allergy to one of the study medications, i.e., rosiglitazone, adalimumab, lisinopril,
losartan or atorvastatin

Age minimum: 1 Year
Age maximum: 65 Years
Gender: All
Health Condition(s) or Problem(s) studied
Focal Segmental Glomerulosclerosis
Drug: Adalimumab
Drug: galactose
Drug: Lisinopril, losartan, and atorvastatin
Primary Outcome(s)
Number of Participants With a Reduction in Proteinuria at 6 Months by > 50% of the Value at Screening AND Stable GFR Defined as Greater Than 75 ml/Min/1.73m2 in Those With an Initial Value Above 90 OR Within 25% of Baseline for Remaining Patients [Time Frame: baseline and 6 months]
Secondary Outcome(s)
Number of Participants With Adverse Events [Time Frame: Up to 7 months]
Patient Satisfaction Score Using the Treatment Satisfaction Questionnaire for Medication (TSQM Questionnaire) [Time Frame: Baseline and 6 months]
Percent Change in or Time to Doubling of Serum Creatinine [Time Frame: Baseline and 6 months]
Percent Change in Proteinuria [Time Frame: Baseline and 6 months]
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The Cleveland Clinic
University of Michigan
Ethics review
Results available: Yes
Date Posted: 11/07/2016
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history